TISIDB

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus Cytoplasm, cytoskeleton, spindle
Domain	PF00225 Kinesin motor domain
Function	Mitotic kinesin required for chromosome passenger complex (CPC)-mediated cytokinesis. Following phosphorylation by PLK1, involved in recruitment of PLK1 to the central spindle. Interacts with guanosine triphosphate (GTP)-bound forms of RAB6A and RAB6B. May act as a motor required for the retrograde RAB6 regulated transport of Golgi membranes and associated vesicles along microtubules. Has a microtubule plus end-directed motility.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0000281 mitotic cytokinesis GO:0000910 cytokinesis GO:0000920 cell separation after cytokinesis GO:0001578 microtubule bundle formation GO:0007018 microtubule-based movement GO:0061640 cytoskeleton-dependent cytokinesis
Molecular Function	GO:0003774 motor activity GO:0003777 microtubule motor activity GO:0008017 microtubule binding GO:0015631 tubulin binding GO:0016887 ATPase activity
Cellular Component	GO:0005819 spindle GO:0005871 kinesin complex GO:0005874 microtubule GO:0005875 microtubule associated complex GO:0030496 midbody

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-8856688: Golgi-to-ER retrograde transport R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic R-HSA-983189: Kinesins R-HSA-68886: M Phase R-HSA-2132295: MHC class II antigen presentation R-HSA-199991: Membrane Trafficking R-HSA-68884: Mitotic Telophase/Cytokinesis R-HSA-5653656: Vesicle-mediated transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-983189: Kinesins
R-HSA-68886: M Phase
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-68884: Mitotic Telophase/Cytokinesis
R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KIF20A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between KIF20A and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23714729	Malignant Head and Neck Neoplasm	Promote immunity (T cell function); essential for immunotherapy	We identified promiscuous KIF20A-LPs bearing naturally processed epitopes recognized by CD4(+) T cells and CTLs. KIF20A-specific CTLs were induced by vaccination with a KIF20A-LP in vivo. KIF20A expression was detected in 55% of HNMT by immunohistochemistry, and significant frequencies of KIF20A-specific TH1 cell responses were detected after short-term in vitro stimulation of PBMCs with KIF20A-LPs in 50% of HNMT patients, but not in healthy donors. Furthermore, these responses were associated with KIF20A expression in HNMT tissues.

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KIF20A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KIF20A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.608	0.0572
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.729	0.566
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.528	0.625
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.172	0.671
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.143	0.924
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.572	0.765
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.073	0.853
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.569	0.674
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.608	0.649
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.129	0.878
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.36	0.763
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.435	0.00154

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KIF20A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	7.4	-7.4	0.169
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIF20A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIF20A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIF20A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIF20A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KIF20A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KIF20A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KIF20A
Name	kinesin family member 20A
Aliases	RAB6KIFL; RAB6 interacting, kinesin-like (rabkinesin6); MKLP2; GG10_2; mitotic kinesin-like protein 2; rab6- ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KIF20A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KIF20A